PHARMARON (03759) has announced that its board of directors has resolved and approved several proposals, including: (i) a recommendation to increase the company's registered capital; and (ii) a recommendation to amend the company's articles of association. This decision follows (i) the placement of a total of 58.4408 million new H shares on January 22, 2026; and (ii) the registration and listing of a total of 647,300 restricted A shares, which vested under the fourth vesting period of the 2021 A-share incentive plan and the third vesting period of the 2022 A-share incentive plan, completed on January 29, 2026. Consequently, the board recommends changing the company's registered capital from RMB 1.778 billion (representing 1.778 billion shares) to RMB 1.837 billion (representing 1.837 billion shares).